NEJM: Effect of dexamisson on prognosis in patients with chronic epidural hematoma

Chronic epidural hematoma is a common neurological disease, especially in the elderly, generally mainly surgical treatment.
recently examined the effects of dexamisson on the prognosis of patients with chronic epidural hematoma.
The study, conducted in the UK, involved adult patients with symptomatic chronic epidural hematoma, who were randomly treated with 2 weeks of dexomison, 2 times a day, 8mg or placebo, with surgery to remove hematoma.
results of the study improved Rankin's score after 6 months, with 0-3 points representing a good prognostic and 6 points representing patient death.
748 patients participated in the study, including 375 in the dexamison group, 373 in the placebo group, with an average age of 74 years, 94 percent of patients who underwent hematoma removal surgery upon hospitalization, and 60 percent of the participants in the hospital rate between 1 and 3.
study found that 286 of the 341 patients in the dexomethon group had good prognosis, while 306 of the 339 patients in the placebo group had a good prognosis (83.9 vs. 90.3%, with a difference of -6.4%).
of the 349 patients in the dexamisson group, 6 underwent secondary surgery for recurrence, while 25 of the placebos had relapsed for secondary surgery (1.7% vs. 7.1%).
high rate of adverse events in the Samisson group.
study concluded that for patients with chronic epidural hematoma, dexomison therapy had no significant advantage in improving the prognosis of patients, but the effect of preventing hematoma recurrence was better than that of placebo.
。